All In Biotech

Drug Trial Radar · NCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

330

Planned (sponsor's estimate)

Start

Jun 12, 2024

Primary completion

Aug 2028

Study completion Feb 2029

Sponsor

Sponsor type
Industry
First posted
Feb 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

Conditions

  • Biliary Tract Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colon Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastric Cancer
  • GastroEsophageal Cancer
  • Head and Neck Cancer
  • Hepatocellular Cancer
  • Non-small Cell Lung Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Rectal Cancer
  • Renal Cancer
  • Thyroid Cancer
  • Urothelial Carcinoma (UC)
  • Cholangiocarcinoma
  • Mesothelioma
  • Gallbladder Cancer
  • Ovarian Cancer

Interventions

  • MDX2001Drug

    MDX2001 intravenous infusion or subcutaneous (SC) injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All Phases: Adverse events (AEs)Time frame: Baseline until end of study, up to approximately 9 months
  2. Phase 1b and Phase 2a: Objective response rate of MDX2001Time frame: From date of enrollment until the end of treatment, up to approximately 6 months
  3. Phase 1: Recommended Phase 2 dose (RP2D)Time frame: Baseline until end of study, up to approximately 9 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Sarah Cannon Research Institute

    Denver, Colorado · Recruiting

  • Sylvester Comprehensive Cancer Center - University of Miami Health System

    Miami, Florida · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.